Prediction of hypertension, diabetes and fractures in eucortisolemic women by measuring parameters of cortisol milieu.
11βhydroxysteroid dehydrogenase
Cortisol
Diabetes
Fractures
Hypertension
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
27
09
2019
accepted:
17
01
2020
pubmed:
29
1
2020
medline:
22
6
2021
entrez:
29
1
2020
Statut:
ppublish
Résumé
Cortisol secretion, peripheral activation, and sensitivity seem to be associated with hypertension (HY), type 2 diabetes (T2D), and fragility fractures (FX) even in eucortisolemic subjects. The aim of the present study was to determine the cutoff(s) of the parameters of cortisol secretion and peripheral activation for predicting the presence of HY, T2D, and FX (comorbidities). In 206 postmenopausal females (157 with ≥1 comorbidities and 49 without any), we assessed the ratio between 24-h urinary free cortisol and cortisone (R-UFF/UFE, cortisol activation index), cortisol after 1 mg-overnight-dexamethasone (F-1mgDST, cortisol secretion index), and the GC receptor N363S single-nucleotide polymorphism (N363S-SNP, cortisol sensitivity index). The cutoffs for F-1mgDST and R-UFF/UFE were set at 0.9 μg/dL (area under the curve, AUC 0.634 ± 0.43, p = 0.005) and 0.17 (AUC 0.624 ± 0.5, p = 0.017), respectively, predicted the presence of ≥1 comorbidities. The presence of F-1mgDST > 0.9 μg/dL plus R-UFF/UFE > 0.17 showed 82.1% specificity for predicting the presence of ≥1 comorbidities, while the simultaneous presence of F-1mgDST ≤ 0.9 μg/dL and R-UFF/UFE ≤ 0.17 showed 88% sensitivity for predicting the absence of comorbidities. The F-1mgDST > 0.9 μg/dL or R-UFF/UFE > 0.17 was associated with 2.8 and 2.1-fold increased risk of having ≥1 comorbidities, respectively. The F-1mgDST ≤ 0.9 μg/dL plus R-UFF/UFE ≤ 0.17 or F-1mgDST > 0.9 μg/dL plus R-UFF/UFE > 0.17 was associated with 2.8-fold reduced or 4.9-fold increased risk of having ≥1 comorbidities regardless of age, BMI, and N363S-SNP. F-1mgDST > 0.9 μg/dL and R-UFF/UFE > 0.17 may be used for predicting the presence of ≥1 among HY, T2D, and fragility FX.
Identifiants
pubmed: 31989409
doi: 10.1007/s12020-020-02212-9
pii: 10.1007/s12020-020-02212-9
doi:
Substances chimiques
Cortisone
V27W9254FZ
Hydrocortisone
WI4X0X7BPJ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
411-419Subventions
Organisme : Istituto Auxologico Italiano
ID : PRECOR STUDY 2019_01_29_06
Pays : International
Organisme : Ministero della Salute
ID : RF 2013 -02356606
Pays : International
Références
R. Pivonello, A.M. Isidori, M.C. De Martino, J. Newell-Price, B.M.K. Biller, A. Colao, Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 4, 611–629 (2016)
doi: 10.1016/S2213-8587(16)00086-3
I. Chiodini, V. Morelli, Subclinical hypercortisolism: how to deal with it? Front. Horm. Res. 46, 28–38 (2016)
doi: 10.1159/000443862
E. Mazgelytė, D. Karčiauskaitė, A. Linkevičiūtė, A. Mažeikienė, N. Burokienė, R. Matuzevičienė, M. Radzevičius, A. Janiulionienė, A. Jakaitienė, L. Dindienė, Z.A. Kučinskienė, Association of hair cortisol concentration with prevalence of major cardiovascular risk factors and allostatic load.Med. Sci. Monit. 25, 3573–3582 (2019)
doi: 10.12659/MSM.913532
A.A. Crawford, S. Söderberg, C. Kirschbaum, L. Murphy, M. Eliasson, S. Ebrahim, G. Davey Smith, T. Olsson, N. Sattar, D.A. Lawlor, N.J. Timpson, R.M. Reynolds, B.R. Walker, Morning plasma cortisol as a cardiovascular risk factor: findings from prospective cohort and Mendelian randomization studies. Eur. J. Endocrinol. (2019). https://doi.org/10.1530/EJE-19-0161
A.V. Haas, P.N. Hopkins, N.J. Brown, L.H. Pojoga, J.S. Williams, G.K. Adler, G.H. Williams, Higher urinary cortisol levels associate with increased cardiovascular risk. Endocr. Conn. 8, 634–640 (2019)
doi: 10.1530/EC-19-0182
I. Chiodini, G. Adda, A. Scillitani, F. Coletti, V. Morelli, S. Di Lembo, P. Epaminonda, B. Masserini, P. Beck-Peccoz, E. Orsi, B. Ambrosi, M. Arosio, Cortisol secretion in patients with type 2 diabetes. Diabetes Care 30, 83–88 (2007)
doi: 10.2337/dc06-1267
V.L. Wester, J.W. Koper, E.L.T. van den Akker, O.H. Franco, R.P. Stolk, E.F.C. van Rossum, Glucocorticoid receptor haplotype and metabolic syndrome: the lifelines cohort study. Eur. J. Endocrinol. 175, 645–651 (2016)
doi: 10.1530/EJE-16-0534
J. Rosenstock, S. Banarer, V.A. Fonseca, S.E. Inzucchi, W. Sun, W. Yao, G. Hollis, R. Flores, R. Levy, W.V. Williams, J.R. Seckl, R. Huber, The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 33, 1516–1522 (2010)
doi: 10.2337/dc09-2315
C.G. Schnackenberg, M.H. Costell, D.J. Krosky, J. Cui, C.W. Wu, V.S. Hong, M.R. Harpel, R.N. Willette, T.L. Yue, Chronic inhibition of 11 β -hydroxysteroid dehydrogenase type 1 activity decreases hypertension, insulin resistance, and hypertriglyceridemia in metabolic syndrome. Biomed. Res. Int. 2013, 427640 (2013)
R.M. Reynolds, E.M. Dennison, B.R. Walker, H.E. Syddall, P.J. Wood, R. Andrew, D.I. Phillips, C. Cooper, Cortisol secretion and rate of bone loss in a population-based cohort of elderly men and women. Calcif. Tissue Int. 77, 134–138 (2005)
doi: 10.1007/s00223-004-0270-2
G. Osella, M. Ventura, A. Ardito, B. Allasino, A. Termine, L. Saba, R. Vitetta, M. Terzolo, A. Angeli, Cortisol secretion, bone health, and bone loss: a cross-sectional and prospective study in normal non-osteoporotic women in the early postmenopausal period. Eur. J. Endocrinol. 166, 855–860 (2012)
doi: 10.1530/EJE-11-0957
J.Y. Hwang, S.H. Lee, G.S. Kim, J.M. Koh, M.J. Go, Y.J. Kim, H.C. Kim, T.H. Kim, J.M. Hong, E.K. Park, J.Y. Lee, S.Y. Kim, HSD11B1 polymorphisms predicted bone mineral density and fracture risk in postmenopausal women without a clinically apparent hypercortisolemia. Bone 45, 1098–1103 (2009)
doi: 10.1016/j.bone.2009.07.080
V.V. Zhukouskaya, C. Eller-Vainicher, A. Gaudio, E. Cairoli, F.M. Ulivieri, S. Palmieri, V. Morelli, E. Orsi, B. Masserini, A.M. Barbieri, E. Polledri, S. Fustinoni, A. Spada, C.E. Fiore, I. Chiodini, In postmenopausal female subjects with type 2 diabetes mellitus, vertebral fractures are independently associated with cortisol secretion and sensitivity. J. Clin. Endocrinol. Metab. 100, 1417–1425 (2015)
doi: 10.1210/jc.2014-4177
I. Chiodini, A. Gaudio, C. Eller-Vainicher, V. Morelli, A. Aresta, V.V. Zhukouskaya, D. Merlotti, E. Orsi, A.M. Barbieri, S. Fustinoni, E. Polledri, L. Gennari, A. Falchetti, V. Carnevale, L. Persani, A. Scillitani, Cortisol secretion, sensitivity, and activity are associated with hypertension in postmenopausal eucortisolemic women. J. Clin. Endocrinol. Metab. 104, 4441–4448 (2019)
doi: 10.1210/jc.2019-00037
S. Fustinoni, E. Polledri, R. Mercadante, High-throughput determination of cortisol, cortisone, and melatonin in oral fluid by on-line turbulent flow liquid chromatography interfaced with liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 27, 1450–1460 (2013)
doi: 10.1002/rcm.6601
V. Morelli, F. Donadio, C. Eller-Vainicher, V. Cirello, L. Olgiati, C. Savoca, E. Cairoli, A.S. Salcuni, P. Beck-Peccoz, I. Chiodini, Role of glucocorticoid receptor polymorphism in adrenal incidentalomas. Eur. J. Clin. Invest 40, 803–811 (2010)
doi: 10.1111/j.1365-2362.2010.02330.x
G. Mancia, R. Fagard, K. Narkiewicz, J. Redon, A. Zanchetti, M. Böhm, T. Christiaens, R. Cifkova, G. De Backer, A. Dominiczak, M. Galderisi, D.E. Grobbee, T. Jaarsma, P. Kirchhof, S.E. Kjeldsen, S. Laurent, A.J. Manolis, P.M. Nilsson, L.M. Ruilope, R.E. Schmieder, P.A. Sirnes, P. Sleight, M. Viigimaa, B. Waeber, F. Zannad, Task force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology: 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press 23, 3–16 (2014)
doi: 10.3109/08037051.2014.868629
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus., Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26, S5–S20 (2003)
doi: 10.2337/diacare.26.11.3160
American Diabetes Association, 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care 42, S13–S28 (2019)
doi: 10.2337/dc19-S002
H.K. Genant, C.Y. Wu, C. van Knijk, M. Nevitt, Vertebral fracture assessment using a semi-quantitative technique. J. Bone Miner. Res. 8, 1137–1148 (1993)
doi: 10.1002/jbmr.5650080915
J.W. Tomlinson, E.A. Walker, I.J. Bujalska, N. Draper, G.G. Lavery, M.S. Cooper, M. Hewison, P.M. Stewart, 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr. Rev. 25(831), 866 (2004)
K. Chapman, M. Holmes, J. Seckl, 11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. Physiol. Rev. 93, 1139–1206 (2013)
doi: 10.1152/physrev.00020.2012
J.W. Koper, E.F. van Rossum, E.L. van den Akker, Glucocorticoid receptor polymorphisms and haplotypes and their expression in health and disease. Steroids 92, 62–73 (2014)
doi: 10.1016/j.steroids.2014.07.015
M.S. Cooper, A. Blumsohn, P.E. Goddard, W.A. Bartlett, C.H. Shackleton, R. Eastell, M. Hewison, P.M. Stewart, 11βhydroxysteroid dehydrogenase type 1 activity predict the effects of glucocorticoids on bone. J. Clin. Endocrinol. Metab. 88, 3874–3877 (2003)
doi: 10.1210/jc.2003-022025
K. Kannisto, K.H. Pietila¨inen, E. Ehrenborg, A. Rissanen, J. Kaprio, A. Hamsten, H. Yki-Ja¨rvinen, Overexpression of 11β-hydroxysteroiddehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J. Clin. Endocrinol. Metab. 89, 4414–4421 (2004)
doi: 10.1210/jc.2004-0153
V. Morelli, G. Reimondo, R. Giordano, S. Della Casa, C. Policola, S. Palmieri, A.S. Salcuni, A. Dolci, M. Mendola, M. Arosio, B. Ambrosi, A. Scillitani, E. Ghigo, P. Beck-Peccoz, M. Terzolo, I. Chiodini, Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J. Clin. Endocrinol. Metab. 99, 827–834 (2014)
doi: 10.1210/jc.2013-3527
I.I. Androulakis, G.A. Kaltsas, G.E. Kollias, A.C. Markou, A.K. Gouli, D.A. Thomas, K.I. Alexandraki, C.M. Papamichael, D.J. Hadjidakis, G.P. Piaditis, Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion. J. Clin. Endocrinol. Metab. 99, 2754–2762 (2014)
doi: 10.1210/jc.2013-4064
D. Lopez, M.A. Luque-Fernandez, A. Steele, G.K. Adler, A. Turchin, A. Vaidya, “Nonfunctional” adrenal tumors and the risk for incident diabetes and cardiovascular outcomes: a cohort study. Ann. Intern. Med. 165, 533–542 (2016)
doi: 10.7326/M16-0547
A. Almasi-Hashiani, M.A Mohammad Ali Mansournia: Methodological issues regarding “cortisol secretion, sensitivity, and activity are associated with hypertension in postmenopausal eucortisolemic women”. J. Clin. Endocrinol. Metab. (2020). (In press). https://doi.org/10.1210/clinem/dgz008
A. Gaudio, L. Gennari, A. Falchetti, A. Scillitani, I. Chiodini, Response to Letter to the Editor: “Methodological issues regarding cortisol secretion, sensitivity, and activity are associated with hypertension in postmenopausal eucortisolemic women. J. Clin. Endocrinol. Metab. (2020). (In press). https://doi.org/10.1210/clinem/dgz009